1. Platoniotis G et al: endometrial cancer: ESMO clinical practice guidlines for diagnosis, treatement and follow-up.
2. Lopez et al: manuale di oncologia medica, Casa Editrice Universo, 2005; 1493- 1449.
3. Balboni G: Anatomia Umana, Casa Editrice edi-ermes,1991; 509-533.
4. Morrow CP et al, Relationship between surgical pathological risk factors and out come in clinical stage I-II carcinoma of endometrium: a Gynecology Oncology Group study. Ginecol Oncol 1991;40:55-65.
5. Yonei A, Yidirim C,Isikji L et al. Prognostic factor and treatment outcome in patients with operated endometrial cancer: analysis of 674 patients at single institution.J.Buon 2011;16:64-73
6. Ferriss JS, Brix W, Tambouret R, DeSimone CP, Stoler M, Modesitt SC. Cervical stromal invasion predicting survival in endometrial cancer. Obstet Gynecol 2010;116:1035-41.
7. Creasman WT et al:Prognostic significante of peritoneal cytology in patients with endometrial cancer and preliminary data concerning theraphy with intraperitoneal radiopharmaceticals. Am J Obset Gynecol 1981; 141:921-8.
8. Suzuki C et al; prognostic significance of the infiltrative pattern invasion in endometrioid adenocarcinoma in endometrial cancer. Pathol Int 2003 ;53:495-500. 9. Creasman WT et al: surgical phatologic spread patterns of endometrial cancer.
Cancer 1987;60:2035.-41
10. Creasman WT et al: Adenocarcinoma of the endometrium : its metastatic lymph node potential. Gynecol Obset 1976; 4:239-43
pag. 54
11. Briet JM et al. Lymphovascular space involvement: an independent prognostic factor in endometrial cancer .Gynecol Oncol 2005;96:799-804
12. Evans M.P., Podratz K.M.: endometrial neoplasia: prognostic significante of ployidy status; Clin Obstet Gynec, 1996;39:696-706.
13. Karlsson B, Valentine L. et al. transvaginal ultrasonography of the endometrium in woman with postmenopausal bleending a Nordic multi center study. Am J Obset Gynecol 1995;172:1488-1494
14. Gu M et al. Pap smears in women with endometrial cancer. Acta Cytol 2001;45:555-60.
15. Bell DJ, Pannu HK et al. Radiological assesment of gynecologic malignancies. Obset Gynecol 2011;38:45-68.
16. Horowitz NS, Dehdashti F, Herzog TJ et al. Prospective evaluation of FDG_PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004;95:546-51
17. Shepherd JH: Revised FIGO staging for gynecological cancer. Obset Gynaecol 1989;96:889-892.
18. Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynecol Obstet 2009;105:103-1046.
19. Boronow RC. Surgical staging of endometrial cancer: evolution, evaluation, and responsible challenge--a personal perspective. Gynecol Oncol 1997;66:179-89. 20. Bremond A, Bataillard A, Thomas L, et al. Standards, Options and
Recommendations for the surgical management of carcinoma of the endometrium. Bull Cancer 2001;88:181-98.
21. Gadducci A, Cosio S, Genazzani AR. Treatment planning in endometrial cancer. Cancer Ther 2003;1:373-91.
pag. 55
22. Susini T, Massi G, Amunni G et al. Vaginal hysterectomy and abdominal hysterectomy for treatment of endometrial cancer in the elderly. Obset Gynecl Surv 2005;60:302-3.
23. Santin AD, Bellone S, O'Brien TJ, Pecorelli S, Cannon MJ, Roman JJ. Current treatment options for endometrial cancer. Expert. Rev. Anticancer Ther 2004;4:679-89.
24. Watanabe Y, Aoki D, Kitagawa R, et al. Status of surgical treatment procedures for endometrial cancer in Japan: results of a Japanese Gynecologic Oncology Group survey. Gynecol Oncol 2007;105:325-8.
25. Candiani GB, Belloni C, Maggi R, Colombo G, Frigoli A, Carinelli SG. Evaluation of different surgical approaches in the treatment of endometrial cancer at FIGO stage I. Gynecol Oncol 1990;37:6-8.
26. Kilgore LC, Partridge EE, Alvarez RD, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995;56:29-33.
27. Onda T, Yoshikawa H, Mizutani K, et al. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br. J. Cancer 1997;75:1836-41.
28. Benedetti Panici P, Maneschi F, Cutillo G, D‟ Andrea G, Manci N, Rabitti C. Anatomical and pathological study of retroperitoneal nodes in endometrial cancer. Int. J. Gynecol. Cancer 1998;8:322-7.
29. Mariani A, Webb MJ, Keeney GL, Calori G, Podratz KC. Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement. Gynecol. Oncol. 2001;83:72-80.
pag. 56
30. Cragun JM, Havrilesky LJ, Calingaert B, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 2005;23:3668-75.
31. Mariani A, Dowdy SC, Cliby WA, et al: Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients. Gynecol Oncol 2006;101:200-8.
32. May K et al: Lymphadenectomy for the management of endometrial cancer (review). The Cochrane Library 2010;1:1-45
33. Panici PB et al. Systematic pelvic lymphadenectomy vsno lymphadenectomy in early stage endometrial carcinoma.J NCI 2008;100:1707-16
34. Kitchener HC et al. efficacy of systematic lymphadenectomy in endometrial cancer (ASTEC trial): a randomized study. Lancet 2009;373:125-136
35. Ballester M, Dubernard G, Rouzier R. et al. Detection Rate and Diagnostic Accuracy of Sentinel-Node Biopsy in Early Stage Endometrial Cancer: A Prospective Multicentre Study (SENTI-ENDO). Lancet Oncol 2011;12:469-76 36. Huguenin P, Baumert B, Lutolf UM, et al. Curative radiotherapy in elderly patients
with endometrial cancer. Patterns of relapse, toxicity and quality of life. Strahlenther Onkol 1999;175:309 –314.
37. Kucera H, Knocke TH, Kucera E, et al. Treatment of endometrial carcinoma with high-dose-rate brachytherapy alone in medically inoperable stage I patients. Acta Obstet Gynecol Scand 1998;77:1008 –1012.
38. Grigsby PW, Kuske RR, Perez CA, Walz BJ, Camel MH, Kao MS, et al. Medically inoperable stage I adenocarcinoma of the endometrium treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 1987;13:483-488.
pag. 57
39. Knocke TH, Kucera H, Weidinger B, Holler W, Potter R. Primary treatment of endometrial carcinoma with high-dose-rate brachytherapy: results of 12 years of experience with 280 patients. Int J Radiat Oncol Biol Phys 1997;37:359-365. 40. Kupelian PA, Eifel PJ, Tornos C, Burke TW, Delclos L, Oswald MJ. Treatment of
endometrial carcinoma with radiation therapy alone. Int J Radiat Oncol Biol Phys 1993;27:817-824.
41. Nguyen TD, Petereit DG. High-dose-rate brachytherapy for medically inoperable stage I endometrial cancer. Gynecol Oncol 1998;71:196 –203.
42. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56:419-427.
43. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam- Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404-1411.
44. Keys HM, et al;. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744-751.
45. Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen- Banasik EM, Mens JW, Slot A, Smit VT, Creutzberg CL, Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Results of the randomized PORTEC-2 trial. J Clin Oncol 2008,26,20S:5503 46. Nout RA, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, et al, Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 Trial, J Clin Oncol 27:3547-3556,2009
pag. 58
47. The ASTEC/EN.5 writing committee on behalf of the ASTEC/EN.5 Study Group: Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis, Lancet 2009; 373:137–46.
48. Maggi R, Lissoni A, Spina A, Melpignano M, Zola P, Favalli G, Colombo A and Fossati R Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. British Journal of Cancer 2006; 95,266– 271.
49. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, Kudo R; Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:226-33 50. Hogberg T, Rosenberg P, Kristensen G, de Oliveira CF, de Pont Christensen R,
Sorbe B, Lundgren C, Salmi T, Andersson H, Reed NS. A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings 25: 5503
51. Aalders JG, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol 1984; 17: 85- 103.
52. Greven K, Olds W. Isolated vaginal recurrences of endometrial adenocarcinoma and their management. Cancer 1987;60:419-421.
53. Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int. J. Radiation Oncology Biol Phys 2003;56:1366–1372,
pag. 59
54. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam- Rodenhuis CC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 2003;89:201– 9.
55. Trope C, Kristensen G. Current status of chemotherapy in gynecologic cancer. Semin. Oncol. 1997;24: S15-S22 .
56. Thigpen T, Vance RB, Khansur Y. The platinum compounds in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 1995; 22: 67-75. 57. Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the
pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol 2006;58:242-56.
58. Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A,Oliver T; Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 2006;101:158-67.
59. Pectasides D, Pectasides E, Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev 2007;33:177-90
60. McMeekin DS. Updates in chemotherapy in the treatment of advanced and recurrent endometrial cancer. Int J Gynecol Cancer 2005;15:407-8
61. Randall ME,Filiaci VL, Muss H et al. Randomized phase III trial of whole abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial cancer: a Gynecologic Oncology Group study, J Clin Oncol 2006;24:36-44.
62. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22:2159-. 66
pag. 60
63. Hoskins PJ, Swenerton KD, Pike JA, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001;19:4048-53.
64. Akram T, Maseelall P, Fanning J. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am J Obstet Gynecol 2005;192:1365-7 65. Vaidya AP, Littell R, Krasner C, Duska LR. Treatment of uterine papillary serous
carcinoma with platinum-based chemotherapy and paclitaxel. Int J Gynecol Cancer 2006;16:267-72.
66. Arimoto T, Nakagawa S, Yasugi T, Yoshikawa H, Kawana K, Yano T, Taketani Y. Treatment with paclitaxel plus carboplatin, alone or with irradiation, of advanced or recurrent endometrial carcinoma. Gynecol Oncol 2007;104:32-5.
67. Sovak MA, Dupont J, Hensley ML, et al. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer 2007;17:197-203.
68. McMeekin DS. Updates in chemotherapy in the treatment of advanced and recurrent endometrial cancer. Int J Gynecol Cancer 2005;15:407-8.
69. Kawashima K. Dose specification in external irradiation with special reference to ICRU report n 29: a physical aspect. Rinsho Hoshasen 1980;11: 1253-4
70. Monti AF, Ostinelli A., Frigerio M. An ICRU 50 radiotherapy treatment chart. Radiother Oncol 1995;35:145-150.
71. Stroom C., Heijmen B.Geometrical uncertainties, radiotherapy planning margin and the ICRU-62 report. Radiother Oncol 2002;64:75-83.
72. Small W et al; Consensus Guidelines for delineation of the intensity modulated pelvic radiotherapy CTV in the post operative treatment of endometrial cancer. 73. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse
pag. 61
74. Hogberg T,Signorelli M. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur K Cancer 2010;46:2422-31
75. Sorbe B, Nordström B, Johanna Mäenpää et al, Intravaginal Brachytherapy in FIGO Stage I Low-Risk Endometrial Cancer A Controlled Randomized Study; Int J Gynecol Cancer 2009; 19: 873-878,
76. Salama JK, Mundt AJ, Roeske J, Mehta N. Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies. Int J Radiat Oncol Bio Phys 2006;65:1170–6.
77. Hogberg T,Signorelli M. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur K Cancer 2010;46:2422-31.
78. NationalCancerIstitute,PORTEC3. Available from http://www.cancer goc/search/ViewClinicalTrials aspx?cdrid=5214478 protocolsearchchid=4206096 version =health professional